nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—CYP3A4—bone cancer	0.364	0.505	CbGaD
Pomalidomide—PTGS2—bone cancer	0.356	0.495	CbGaD
Pomalidomide—PTGS2—Cisplatin—bone cancer	0.0599	0.527	CbGbCtD
Pomalidomide—ABCB1—Cisplatin—bone cancer	0.0198	0.174	CbGbCtD
Pomalidomide—ABCB1—Doxorubicin—bone cancer	0.0132	0.116	CbGbCtD
Pomalidomide—ABCB1—Methotrexate—bone cancer	0.0128	0.113	CbGbCtD
Pomalidomide—CYP3A4—Doxorubicin—bone cancer	0.00793	0.0698	CbGbCtD
Pomalidomide—TNF—amb2 Integrin signaling—MST1R—bone cancer	0.00375	0.0894	CbGpPWpGaD
Pomalidomide—Lenalidomide—PTGS2—bone cancer	0.00239	0.625	CrCbGaD
Pomalidomide—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00239	0.0569	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—FOLR1—bone cancer	0.00179	0.0426	CbGpPWpGaD
Pomalidomide—Thalidomide—PTGS2—bone cancer	0.00143	0.375	CrCbGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—FEV—bone cancer	0.00106	0.0252	CbGpPWpGaD
Pomalidomide—ABCB1—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000986	0.0235	CbGpPWpGaD
Pomalidomide—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000923	0.022	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.000921	0.022	CbGpPWpGaD
Pomalidomide—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000875	0.0209	CbGpPWpGaD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL3—bone cancer	0.00085	0.0203	CbGpPWpGaD
Pomalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000783	0.0187	CbGpPWpGaD
Pomalidomide—Hypokalaemia—Cisplatin—bone cancer	0.000639	0.00528	CcSEcCtD
Pomalidomide—Breast disorder—Cisplatin—bone cancer	0.000634	0.00524	CcSEcCtD
Pomalidomide—Nasopharyngitis—Cisplatin—bone cancer	0.000627	0.00519	CcSEcCtD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000605	0.0144	CbGpPWpGaD
Pomalidomide—Hyperbilirubinaemia—Methotrexate—bone cancer	0.000583	0.00482	CcSEcCtD
Pomalidomide—Pancytopenia—Cisplatin—bone cancer	0.000576	0.00476	CcSEcCtD
Pomalidomide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000569	0.0136	CbGpPWpGaD
Pomalidomide—Hyperbilirubinaemia—Epirubicin—bone cancer	0.000546	0.00451	CcSEcCtD
Pomalidomide—Hypocalcaemia—Epirubicin—bone cancer	0.000542	0.00448	CcSEcCtD
Pomalidomide—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000539	0.0129	CbGpPWpGaD
Pomalidomide—Renal failure—Cisplatin—bone cancer	0.000532	0.00439	CcSEcCtD
Pomalidomide—Pulmonary embolism—Methotrexate—bone cancer	0.00053	0.00438	CcSEcCtD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00053	0.0126	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Cisplatin—bone cancer	0.00053	0.00438	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000519	0.0124	CbGpPWpGaD
Pomalidomide—Bone pain—Epirubicin—bone cancer	0.000518	0.00428	CcSEcCtD
Pomalidomide—Depressed level of consciousness—Methotrexate—bone cancer	0.000512	0.00423	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Cisplatin—bone cancer	0.000511	0.00423	CcSEcCtD
Pomalidomide—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.000505	0.00417	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Epirubicin—bone cancer	0.000502	0.00415	CcSEcCtD
Pomalidomide—Hypocalcaemia—Doxorubicin—bone cancer	0.000502	0.00415	CcSEcCtD
Pomalidomide—TNF—Overview of nanoparticle effects—PTGS2—bone cancer	0.000499	0.0119	CbGpPWpGaD
Pomalidomide—Pulmonary embolism—Epirubicin—bone cancer	0.000496	0.0041	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.000496	0.0118	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—DHFR—bone cancer	0.00049	0.0117	CbGpPWpGaD
Pomalidomide—Hyperkalaemia—Epirubicin—bone cancer	0.000488	0.00403	CcSEcCtD
Pomalidomide—TNF—amb2 Integrin signaling—PLAU—bone cancer	0.000486	0.0116	CbGpPWpGaD
Pomalidomide—Bone pain—Doxorubicin—bone cancer	0.000479	0.00396	CcSEcCtD
Pomalidomide—Urinary tract disorder—Cisplatin—bone cancer	0.000479	0.00396	CcSEcCtD
Pomalidomide—Connective tissue disorder—Cisplatin—bone cancer	0.000477	0.00394	CcSEcCtD
Pomalidomide—Urethral disorder—Cisplatin—bone cancer	0.000476	0.00393	CcSEcCtD
Pomalidomide—Neuropathy—Epirubicin—bone cancer	0.000466	0.00385	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Doxorubicin—bone cancer	0.000465	0.00384	CcSEcCtD
Pomalidomide—Sepsis—Methotrexate—bone cancer	0.00046	0.0038	CcSEcCtD
Pomalidomide—Pulmonary embolism—Doxorubicin—bone cancer	0.000459	0.0038	CcSEcCtD
Pomalidomide—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000452	0.0108	CbGpPWpGaD
Pomalidomide—Hyperkalaemia—Doxorubicin—bone cancer	0.000451	0.00373	CcSEcCtD
Pomalidomide—Cardiac disorder—Cisplatin—bone cancer	0.00045	0.00372	CcSEcCtD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000438	0.0104	CbGpPWpGaD
Pomalidomide—Mediastinal disorder—Cisplatin—bone cancer	0.000437	0.00362	CcSEcCtD
Pomalidomide—Neuropathy—Doxorubicin—bone cancer	0.000431	0.00356	CcSEcCtD
Pomalidomide—Sepsis—Epirubicin—bone cancer	0.000431	0.00356	CcSEcCtD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000423	0.0101	CbGpPWpGaD
Pomalidomide—Malnutrition—Cisplatin—bone cancer	0.000423	0.00349	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—TGFBR2—bone cancer	0.000417	0.00995	CbGpPWpGaD
Pomalidomide—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000411	0.0098	CbGpPWpGaD
Pomalidomide—Muscle spasms—Cisplatin—bone cancer	0.000406	0.00336	CcSEcCtD
Pomalidomide—TNF—Matrix Metalloproteinases—MMP2—bone cancer	0.000404	0.00963	CbGpPWpGaD
Pomalidomide—Sepsis—Doxorubicin—bone cancer	0.000399	0.00329	CcSEcCtD
Pomalidomide—Cardiac failure congestive—Epirubicin—bone cancer	0.000397	0.00328	CcSEcCtD
Pomalidomide—Tremor—Cisplatin—bone cancer	0.000396	0.00327	CcSEcCtD
Pomalidomide—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000394	0.00939	CbGpPWpGaD
Pomalidomide—Anaemia—Cisplatin—bone cancer	0.000391	0.00323	CcSEcCtD
Pomalidomide—TNF—amb2 Integrin signaling—MMP2—bone cancer	0.000383	0.00914	CbGpPWpGaD
Pomalidomide—Leukopenia—Cisplatin—bone cancer	0.000378	0.00313	CcSEcCtD
Pomalidomide—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000378	0.00901	CbGpPWpGaD
Pomalidomide—Cardiac failure congestive—Doxorubicin—bone cancer	0.000368	0.00304	CcSEcCtD
Pomalidomide—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000364	0.00867	CbGpPWpGaD
Pomalidomide—Hyponatraemia—Epirubicin—bone cancer	0.000362	0.00299	CcSEcCtD
Pomalidomide—Pain in extremity—Epirubicin—bone cancer	0.00036	0.00298	CcSEcCtD
Pomalidomide—Anxiety—Cisplatin—bone cancer	0.000358	0.00296	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000357	0.00295	CcSEcCtD
Pomalidomide—Breast disorder—Methotrexate—bone cancer	0.000348	0.00288	CcSEcCtD
Pomalidomide—Infection—Cisplatin—bone cancer	0.000343	0.00283	CcSEcCtD
Pomalidomide—Nervous system disorder—Cisplatin—bone cancer	0.000338	0.0028	CcSEcCtD
Pomalidomide—Thrombocytopenia—Cisplatin—bone cancer	0.000338	0.00279	CcSEcCtD
Pomalidomide—Blood creatinine increased—Epirubicin—bone cancer	0.000338	0.00279	CcSEcCtD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000337	0.00804	CbGpPWpGaD
Pomalidomide—Dehydration—Epirubicin—bone cancer	0.000335	0.00277	CcSEcCtD
Pomalidomide—Skin disorder—Cisplatin—bone cancer	0.000335	0.00277	CcSEcCtD
Pomalidomide—Hyponatraemia—Doxorubicin—bone cancer	0.000335	0.00277	CcSEcCtD
Pomalidomide—Pain in extremity—Doxorubicin—bone cancer	0.000333	0.00276	CcSEcCtD
Pomalidomide—Hyperhidrosis—Cisplatin—bone cancer	0.000333	0.00276	CcSEcCtD
Pomalidomide—Dry skin—Epirubicin—bone cancer	0.00033	0.00273	CcSEcCtD
Pomalidomide—Hypokalaemia—Epirubicin—bone cancer	0.000328	0.00271	CcSEcCtD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000327	0.00779	CbGpPWpGaD
Pomalidomide—Breast disorder—Epirubicin—bone cancer	0.000326	0.00269	CcSEcCtD
Pomalidomide—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000325	0.00775	CbGpPWpGaD
Pomalidomide—Nasopharyngitis—Epirubicin—bone cancer	0.000322	0.00266	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000322	0.00767	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—RB1—bone cancer	0.000322	0.00767	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.000321	0.00765	CbGpPWpGaD
Pomalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000319	0.00761	CbGpPWpGaD
Pomalidomide—Muscular weakness—Epirubicin—bone cancer	0.000318	0.00263	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000318	0.00263	CcSEcCtD
Pomalidomide—Pancytopenia—Methotrexate—bone cancer	0.000316	0.00261	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000314	0.0026	CcSEcCtD
Pomalidomide—Blood creatinine increased—Doxorubicin—bone cancer	0.000312	0.00258	CcSEcCtD
Pomalidomide—Neutropenia—Methotrexate—bone cancer	0.000311	0.00257	CcSEcCtD
Pomalidomide—Dehydration—Doxorubicin—bone cancer	0.00031	0.00256	CcSEcCtD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00031	0.00738	CbGpPWpGaD
Pomalidomide—Upper respiratory tract infection—Methotrexate—bone cancer	0.000309	0.00256	CcSEcCtD
Pomalidomide—Dyspnoea—Cisplatin—bone cancer	0.000307	0.00254	CcSEcCtD
Pomalidomide—Dry skin—Doxorubicin—bone cancer	0.000306	0.00253	CcSEcCtD
Pomalidomide—TNF—Matrix Metalloproteinases—MMP9—bone cancer	0.000304	0.00724	CbGpPWpGaD
Pomalidomide—Hypokalaemia—Doxorubicin—bone cancer	0.000303	0.00251	CcSEcCtD
Pomalidomide—Breast disorder—Doxorubicin—bone cancer	0.000301	0.00249	CcSEcCtD
Pomalidomide—Decreased appetite—Cisplatin—bone cancer	0.0003	0.00248	CcSEcCtD
Pomalidomide—Bronchitis—Epirubicin—bone cancer	0.000299	0.00248	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000299	0.00713	CbGpPWpGaD
Pomalidomide—Pneumonia—Methotrexate—bone cancer	0.000298	0.00247	CcSEcCtD
Pomalidomide—Nasopharyngitis—Doxorubicin—bone cancer	0.000298	0.00246	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000298	0.00246	CcSEcCtD
Pomalidomide—Infestation NOS—Methotrexate—bone cancer	0.000297	0.00245	CcSEcCtD
Pomalidomide—Infestation—Methotrexate—bone cancer	0.000297	0.00245	CcSEcCtD
Pomalidomide—Pancytopenia—Epirubicin—bone cancer	0.000296	0.00244	CcSEcCtD
Pomalidomide—Pain—Cisplatin—bone cancer	0.000295	0.00244	CcSEcCtD
Pomalidomide—Muscular weakness—Doxorubicin—bone cancer	0.000294	0.00243	CcSEcCtD
Pomalidomide—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000294	0.00243	CcSEcCtD
Pomalidomide—Renal failure—Methotrexate—bone cancer	0.000292	0.00241	CcSEcCtD
Pomalidomide—Neutropenia—Epirubicin—bone cancer	0.000291	0.00241	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Epirubicin—bone cancer	0.000289	0.00239	CcSEcCtD
Pomalidomide—TNF—Ceramide signaling pathway—RB1—bone cancer	0.000289	0.00689	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—MMP9—bone cancer	0.000288	0.00687	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Cisplatin—bone cancer	0.000284	0.00235	CcSEcCtD
Pomalidomide—Weight increased—Epirubicin—bone cancer	0.000283	0.00234	CcSEcCtD
Pomalidomide—Weight decreased—Epirubicin—bone cancer	0.000282	0.00233	CcSEcCtD
Pomalidomide—Hyperglycaemia—Epirubicin—bone cancer	0.000281	0.00232	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Methotrexate—bone cancer	0.000281	0.00232	CcSEcCtD
Pomalidomide—Epistaxis—Methotrexate—bone cancer	0.00028	0.00231	CcSEcCtD
Pomalidomide—Pneumonia—Epirubicin—bone cancer	0.000279	0.00231	CcSEcCtD
Pomalidomide—Infestation—Epirubicin—bone cancer	0.000278	0.00229	CcSEcCtD
Pomalidomide—Infestation NOS—Epirubicin—bone cancer	0.000278	0.00229	CcSEcCtD
Pomalidomide—Bronchitis—Doxorubicin—bone cancer	0.000277	0.00229	CcSEcCtD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—IGF1R—bone cancer	0.000276	0.00657	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—IGF1R—bone cancer	0.000276	0.00657	CbGpPWpGaD
Pomalidomide—Pancytopenia—Doxorubicin—bone cancer	0.000274	0.00226	CcSEcCtD
Pomalidomide—Renal failure—Epirubicin—bone cancer	0.000273	0.00226	CcSEcCtD
Pomalidomide—Body temperature increased—Cisplatin—bone cancer	0.000273	0.00225	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Epirubicin—bone cancer	0.000272	0.00225	CcSEcCtD
Pomalidomide—Urinary tract infection—Epirubicin—bone cancer	0.00027	0.00223	CcSEcCtD
Pomalidomide—Neutropenia—Doxorubicin—bone cancer	0.000269	0.00223	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—bone cancer	0.000268	0.0064	CbGpPWpGaD
Pomalidomide—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000268	0.00221	CcSEcCtD
Pomalidomide—Urinary tract disorder—Methotrexate—bone cancer	0.000263	0.00217	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Epirubicin—bone cancer	0.000263	0.00217	CcSEcCtD
Pomalidomide—Weight increased—Doxorubicin—bone cancer	0.000262	0.00217	CcSEcCtD
Pomalidomide—Epistaxis—Epirubicin—bone cancer	0.000262	0.00216	CcSEcCtD
Pomalidomide—Urethral disorder—Methotrexate—bone cancer	0.000261	0.00216	CcSEcCtD
Pomalidomide—Weight decreased—Doxorubicin—bone cancer	0.000261	0.00215	CcSEcCtD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00026	0.0062	CbGpPWpGaD
Pomalidomide—Hyperglycaemia—Doxorubicin—bone cancer	0.00026	0.00215	CcSEcCtD
Pomalidomide—Pneumonia—Doxorubicin—bone cancer	0.000258	0.00214	CcSEcCtD
Pomalidomide—Infestation NOS—Doxorubicin—bone cancer	0.000257	0.00212	CcSEcCtD
Pomalidomide—Infestation—Doxorubicin—bone cancer	0.000257	0.00212	CcSEcCtD
Pomalidomide—Hypersensitivity—Cisplatin—bone cancer	0.000254	0.0021	CcSEcCtD
Pomalidomide—Renal failure—Doxorubicin—bone cancer	0.000253	0.00209	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000252	0.00601	CbGpPWpGaD
Pomalidomide—Neuropathy peripheral—Doxorubicin—bone cancer	0.000252	0.00208	CcSEcCtD
Pomalidomide—Urinary tract infection—Doxorubicin—bone cancer	0.00025	0.00206	CcSEcCtD
Pomalidomide—Asthenia—Cisplatin—bone cancer	0.000247	0.00204	CcSEcCtD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000247	0.00589	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Methotrexate—bone cancer	0.000247	0.00204	CcSEcCtD
Pomalidomide—Urinary tract disorder—Epirubicin—bone cancer	0.000246	0.00203	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000246	0.00586	CbGpPWpGaD
Pomalidomide—Oedema peripheral—Epirubicin—bone cancer	0.000246	0.00203	CcSEcCtD
Pomalidomide—Connective tissue disorder—Epirubicin—bone cancer	0.000245	0.00202	CcSEcCtD
Pomalidomide—Urethral disorder—Epirubicin—bone cancer	0.000244	0.00202	CcSEcCtD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000243	0.0058	CbGpPWpGaD
Pomalidomide—Hepatobiliary disease—Doxorubicin—bone cancer	0.000243	0.00201	CcSEcCtD
Pomalidomide—Epistaxis—Doxorubicin—bone cancer	0.000242	0.002	CcSEcCtD
Pomalidomide—Angiopathy—Methotrexate—bone cancer	0.000242	0.002	CcSEcCtD
Pomalidomide—Mediastinal disorder—Methotrexate—bone cancer	0.00024	0.00198	CcSEcCtD
Pomalidomide—Chills—Methotrexate—bone cancer	0.000239	0.00198	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—JUN—bone cancer	0.000238	0.00568	CbGpPWpGaD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—JUN—bone cancer	0.000238	0.00568	CbGpPWpGaD
Pomalidomide—Diarrhoea—Cisplatin—bone cancer	0.000236	0.00195	CcSEcCtD
Pomalidomide—Mental disorder—Methotrexate—bone cancer	0.000233	0.00193	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—MMP9—bone cancer	0.000232	0.00553	CbGpPWpGaD
Pomalidomide—Malnutrition—Methotrexate—bone cancer	0.000232	0.00192	CcSEcCtD
Pomalidomide—Cardiac disorder—Epirubicin—bone cancer	0.000231	0.00191	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—bone cancer	0.00023	0.00548	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—BRAF—bone cancer	0.000228	0.00543	CbGpPWpGaD
Pomalidomide—Urinary tract disorder—Doxorubicin—bone cancer	0.000228	0.00188	CcSEcCtD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	0.000228	0.00543	CbGpPWpGaD
Pomalidomide—Oedema peripheral—Doxorubicin—bone cancer	0.000227	0.00188	CcSEcCtD
Pomalidomide—Connective tissue disorder—Doxorubicin—bone cancer	0.000227	0.00187	CcSEcCtD
Pomalidomide—Angiopathy—Epirubicin—bone cancer	0.000226	0.00187	CcSEcCtD
Pomalidomide—Urethral disorder—Doxorubicin—bone cancer	0.000226	0.00187	CcSEcCtD
Pomalidomide—Mediastinal disorder—Epirubicin—bone cancer	0.000225	0.00186	CcSEcCtD
Pomalidomide—Back pain—Methotrexate—bone cancer	0.000224	0.00185	CcSEcCtD
Pomalidomide—Chills—Epirubicin—bone cancer	0.000224	0.00185	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000222	0.00528	CbGpPWpGaD
Pomalidomide—Vomiting—Cisplatin—bone cancer	0.000219	0.00181	CcSEcCtD
Pomalidomide—Mental disorder—Epirubicin—bone cancer	0.000218	0.0018	CcSEcCtD
Pomalidomide—Rash—Cisplatin—bone cancer	0.000217	0.0018	CcSEcCtD
Pomalidomide—Dermatitis—Cisplatin—bone cancer	0.000217	0.0018	CcSEcCtD
Pomalidomide—Malnutrition—Epirubicin—bone cancer	0.000217	0.00179	CcSEcCtD
Pomalidomide—Anaemia—Methotrexate—bone cancer	0.000214	0.00177	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000214	0.00511	CbGpPWpGaD
Pomalidomide—Cardiac disorder—Doxorubicin—bone cancer	0.000214	0.00177	CcSEcCtD
Pomalidomide—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000213	0.00508	CbGpPWpGaD
Pomalidomide—Back pain—Epirubicin—bone cancer	0.00021	0.00173	CcSEcCtD
Pomalidomide—Angiopathy—Doxorubicin—bone cancer	0.000209	0.00173	CcSEcCtD
Pomalidomide—Muscle spasms—Epirubicin—bone cancer	0.000209	0.00172	CcSEcCtD
Pomalidomide—Vertigo—Methotrexate—bone cancer	0.000208	0.00172	CcSEcCtD
Pomalidomide—Mediastinal disorder—Doxorubicin—bone cancer	0.000208	0.00172	CcSEcCtD
Pomalidomide—Leukopenia—Methotrexate—bone cancer	0.000208	0.00172	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000207	0.00494	CbGpPWpGaD
Pomalidomide—Chills—Doxorubicin—bone cancer	0.000207	0.00171	CcSEcCtD
Pomalidomide—Nausea—Cisplatin—bone cancer	0.000205	0.00169	CcSEcCtD
Pomalidomide—Cough—Methotrexate—bone cancer	0.000202	0.00167	CcSEcCtD
Pomalidomide—Mental disorder—Doxorubicin—bone cancer	0.000202	0.00167	CcSEcCtD
Pomalidomide—Malnutrition—Doxorubicin—bone cancer	0.000201	0.00166	CcSEcCtD
Pomalidomide—Anaemia—Epirubicin—bone cancer	0.000201	0.00166	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000199	0.00474	CbGpPWpGaD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.000198	0.00473	CbGpPWpGaD
Pomalidomide—Arthralgia—Methotrexate—bone cancer	0.000197	0.00163	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000196	0.00162	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000195	0.00465	CbGpPWpGaD
Pomalidomide—Vertigo—Epirubicin—bone cancer	0.000195	0.00161	CcSEcCtD
Pomalidomide—TNF—TGF-beta Receptor Signaling—JUN—bone cancer	0.000195	0.00465	CbGpPWpGaD
Pomalidomide—Leukopenia—Epirubicin—bone cancer	0.000194	0.00161	CcSEcCtD
Pomalidomide—Back pain—Doxorubicin—bone cancer	0.000194	0.00161	CcSEcCtD
Pomalidomide—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000194	0.00463	CbGpPWpGaD
Pomalidomide—Muscle spasms—Doxorubicin—bone cancer	0.000193	0.0016	CcSEcCtD
Pomalidomide—Confusional state—Methotrexate—bone cancer	0.000191	0.00158	CcSEcCtD
Pomalidomide—Cough—Epirubicin—bone cancer	0.000189	0.00157	CcSEcCtD
Pomalidomide—Infection—Methotrexate—bone cancer	0.000188	0.00155	CcSEcCtD
Pomalidomide—Nervous system disorder—Methotrexate—bone cancer	0.000186	0.00153	CcSEcCtD
Pomalidomide—Anaemia—Doxorubicin—bone cancer	0.000186	0.00153	CcSEcCtD
Pomalidomide—Thrombocytopenia—Methotrexate—bone cancer	0.000185	0.00153	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000185	0.00441	CbGpPWpGaD
Pomalidomide—Arthralgia—Epirubicin—bone cancer	0.000185	0.00153	CcSEcCtD
Pomalidomide—Anxiety—Epirubicin—bone cancer	0.000184	0.00152	CcSEcCtD
Pomalidomide—Skin disorder—Methotrexate—bone cancer	0.000184	0.00152	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000183	0.00152	CcSEcCtD
Pomalidomide—Hyperhidrosis—Methotrexate—bone cancer	0.000183	0.00151	CcSEcCtD
Pomalidomide—Vertigo—Doxorubicin—bone cancer	0.00018	0.00149	CcSEcCtD
Pomalidomide—Leukopenia—Doxorubicin—bone cancer	0.00018	0.00149	CcSEcCtD
Pomalidomide—Confusional state—Epirubicin—bone cancer	0.000179	0.00148	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000178	0.00423	CbGpPWpGaD
Pomalidomide—Infection—Epirubicin—bone cancer	0.000176	0.00145	CcSEcCtD
Pomalidomide—Cough—Doxorubicin—bone cancer	0.000175	0.00145	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000175	0.00418	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000174	0.00415	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000174	0.00415	CbGpPWpGaD
Pomalidomide—Nervous system disorder—Epirubicin—bone cancer	0.000174	0.00144	CcSEcCtD
Pomalidomide—Thrombocytopenia—Epirubicin—bone cancer	0.000173	0.00143	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000172	0.00142	CcSEcCtD
Pomalidomide—Skin disorder—Epirubicin—bone cancer	0.000172	0.00142	CcSEcCtD
Pomalidomide—Hyperhidrosis—Epirubicin—bone cancer	0.000171	0.00141	CcSEcCtD
Pomalidomide—Insomnia—Methotrexate—bone cancer	0.000171	0.00141	CcSEcCtD
Pomalidomide—Arthralgia—Doxorubicin—bone cancer	0.000171	0.00141	CcSEcCtD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000171	0.00407	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—bone cancer	0.00017	0.00406	CbGpPWpGaD
Pomalidomide—Anxiety—Doxorubicin—bone cancer	0.00017	0.00141	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00017	0.0014	CcSEcCtD
Pomalidomide—Dyspnoea—Methotrexate—bone cancer	0.000169	0.00139	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFBR2—bone cancer	0.000168	0.00401	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—JUN—bone cancer	0.000166	0.00396	CbGpPWpGaD
Pomalidomide—Confusional state—Doxorubicin—bone cancer	0.000165	0.00137	CcSEcCtD
Pomalidomide—Decreased appetite—Methotrexate—bone cancer	0.000165	0.00136	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000163	0.00135	CcSEcCtD
Pomalidomide—Fatigue—Methotrexate—bone cancer	0.000163	0.00135	CcSEcCtD
Pomalidomide—Infection—Doxorubicin—bone cancer	0.000163	0.00135	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CDK4—bone cancer	0.000162	0.00386	CbGpPWpGaD
Pomalidomide—Pain—Methotrexate—bone cancer	0.000162	0.00134	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000161	0.00133	CcSEcCtD
Pomalidomide—Nervous system disorder—Doxorubicin—bone cancer	0.000161	0.00133	CcSEcCtD
Pomalidomide—Thrombocytopenia—Doxorubicin—bone cancer	0.00016	0.00133	CcSEcCtD
Pomalidomide—Insomnia—Epirubicin—bone cancer	0.00016	0.00132	CcSEcCtD
Pomalidomide—Skin disorder—Doxorubicin—bone cancer	0.000159	0.00132	CcSEcCtD
Pomalidomide—Hyperhidrosis—Doxorubicin—bone cancer	0.000158	0.00131	CcSEcCtD
Pomalidomide—Dyspnoea—Epirubicin—bone cancer	0.000158	0.0013	CcSEcCtD
Pomalidomide—TNF—Apoptosis—MDM2—bone cancer	0.000157	0.00375	CbGpPWpGaD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000157	0.00374	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Methotrexate—bone cancer	0.000156	0.00129	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000156	0.00371	CbGpPWpGaD
Pomalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000155	0.00369	CbGpPWpGaD
Pomalidomide—Decreased appetite—Epirubicin—bone cancer	0.000154	0.00127	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000153	0.00126	CcSEcCtD
Pomalidomide—Fatigue—Epirubicin—bone cancer	0.000153	0.00126	CcSEcCtD
Pomalidomide—Pain—Epirubicin—bone cancer	0.000151	0.00125	CcSEcCtD
Pomalidomide—Constipation—Epirubicin—bone cancer	0.000151	0.00125	CcSEcCtD
Pomalidomide—Body temperature increased—Methotrexate—bone cancer	0.00015	0.00124	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000149	0.00123	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000148	0.00354	CbGpPWpGaD
Pomalidomide—Insomnia—Doxorubicin—bone cancer	0.000148	0.00122	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—PTGS2—bone cancer	0.000146	0.00349	CbGpPWpGaD
Pomalidomide—Dyspnoea—Doxorubicin—bone cancer	0.000146	0.00121	CcSEcCtD
Pomalidomide—Feeling abnormal—Epirubicin—bone cancer	0.000146	0.00121	CcSEcCtD
Pomalidomide—Decreased appetite—Doxorubicin—bone cancer	0.000142	0.00118	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000141	0.00117	CcSEcCtD
Pomalidomide—Fatigue—Doxorubicin—bone cancer	0.000141	0.00117	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—RB1—bone cancer	0.000141	0.00336	CbGpPWpGaD
Pomalidomide—Constipation—Doxorubicin—bone cancer	0.00014	0.00116	CcSEcCtD
Pomalidomide—Pain—Doxorubicin—bone cancer	0.00014	0.00116	CcSEcCtD
Pomalidomide—Body temperature increased—Epirubicin—bone cancer	0.00014	0.00116	CcSEcCtD
Pomalidomide—Hypersensitivity—Methotrexate—bone cancer	0.000139	0.00115	CcSEcCtD
Pomalidomide—TNF—Apoptosis—JUN—bone cancer	0.000137	0.00326	CbGpPWpGaD
Pomalidomide—Asthenia—Methotrexate—bone cancer	0.000136	0.00112	CcSEcCtD
Pomalidomide—Feeling abnormal—Doxorubicin—bone cancer	0.000135	0.00112	CcSEcCtD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000135	0.00322	CbGpPWpGaD
Pomalidomide—Pruritus—Methotrexate—bone cancer	0.000134	0.00111	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000132	0.00316	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Epirubicin—bone cancer	0.00013	0.00108	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—RB1—bone cancer	0.00013	0.00311	CbGpPWpGaD
Pomalidomide—Body temperature increased—Doxorubicin—bone cancer	0.00013	0.00107	CcSEcCtD
Pomalidomide—Diarrhoea—Methotrexate—bone cancer	0.000129	0.00107	CcSEcCtD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000128	0.00306	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—JUN—bone cancer	0.000127	0.00303	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000127	0.00303	CbGpPWpGaD
Pomalidomide—Asthenia—Epirubicin—bone cancer	0.000127	0.00105	CcSEcCtD
Pomalidomide—Pruritus—Epirubicin—bone cancer	0.000125	0.00104	CcSEcCtD
Pomalidomide—Dizziness—Methotrexate—bone cancer	0.000125	0.00103	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—KIT—bone cancer	0.000124	0.00295	CbGpPWpGaD
Pomalidomide—Diarrhoea—Epirubicin—bone cancer	0.000121	0.001	CcSEcCtD
Pomalidomide—Hypersensitivity—Doxorubicin—bone cancer	0.000121	0.000998	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000121	0.00288	CbGpPWpGaD
Pomalidomide—Vomiting—Methotrexate—bone cancer	0.00012	0.000994	CcSEcCtD
Pomalidomide—Rash—Methotrexate—bone cancer	0.000119	0.000986	CcSEcCtD
Pomalidomide—Dermatitis—Methotrexate—bone cancer	0.000119	0.000985	CcSEcCtD
Pomalidomide—Headache—Methotrexate—bone cancer	0.000119	0.00098	CcSEcCtD
Pomalidomide—Asthenia—Doxorubicin—bone cancer	0.000118	0.000972	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—JUN—bone cancer	0.000117	0.00279	CbGpPWpGaD
Pomalidomide—Dizziness—Epirubicin—bone cancer	0.000117	0.000968	CcSEcCtD
Pomalidomide—Pruritus—Doxorubicin—bone cancer	0.000116	0.000958	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—PTGS2—bone cancer	0.000116	0.00276	CbGpPWpGaD
Pomalidomide—Vomiting—Epirubicin—bone cancer	0.000113	0.000931	CcSEcCtD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000113	0.00268	CbGpPWpGaD
Pomalidomide—Nausea—Methotrexate—bone cancer	0.000112	0.000929	CcSEcCtD
Pomalidomide—Diarrhoea—Doxorubicin—bone cancer	0.000112	0.000927	CcSEcCtD
Pomalidomide—Rash—Epirubicin—bone cancer	0.000112	0.000923	CcSEcCtD
Pomalidomide—Dermatitis—Epirubicin—bone cancer	0.000112	0.000922	CcSEcCtD
Pomalidomide—Headache—Epirubicin—bone cancer	0.000111	0.000917	CcSEcCtD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00011	0.00263	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00011	0.00262	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00011	0.00262	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—bone cancer	0.00011	0.00261	CbGpPWpGaD
Pomalidomide—Dizziness—Doxorubicin—bone cancer	0.000108	0.000896	CcSEcCtD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000108	0.00258	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—BRAF—bone cancer	0.000108	0.00257	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000108	0.00257	CbGpPWpGaD
Pomalidomide—Nausea—Epirubicin—bone cancer	0.000105	0.000869	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000105	0.00249	CbGpPWpGaD
Pomalidomide—Vomiting—Doxorubicin—bone cancer	0.000104	0.000861	CcSEcCtD
Pomalidomide—Rash—Doxorubicin—bone cancer	0.000103	0.000854	CcSEcCtD
Pomalidomide—Dermatitis—Doxorubicin—bone cancer	0.000103	0.000853	CcSEcCtD
Pomalidomide—Headache—Doxorubicin—bone cancer	0.000103	0.000848	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—MMP9—bone cancer	0.000101	0.00242	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDK4—bone cancer	0.0001	0.00239	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GSTP1—bone cancer	9.88e-05	0.00236	CbGpPWpGaD
Pomalidomide—Nausea—Doxorubicin—bone cancer	9.73e-05	0.000804	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—TP53—bone cancer	9.49e-05	0.00226	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	9.39e-05	0.00224	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	9.18e-05	0.00219	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—JUN—bone cancer	9.15e-05	0.00218	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—bone cancer	9.04e-05	0.00215	CbGpPWpGaD
Pomalidomide—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	8.92e-05	0.00213	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—RB1—bone cancer	8.7e-05	0.00208	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	8.6e-05	0.00205	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	8.55e-05	0.00204	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—JUN—bone cancer	8.34e-05	0.00199	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—EGFR—bone cancer	8.2e-05	0.00195	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	8.16e-05	0.00195	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	8.05e-05	0.00192	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	7.87e-05	0.00188	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—JUN—bone cancer	7.86e-05	0.00187	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	7.79e-05	0.00186	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	7.76e-05	0.00185	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.68e-05	0.00183	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	7.28e-05	0.00174	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NDUFA12—bone cancer	7.16e-05	0.00171	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.1e-05	0.00169	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	6.89e-05	0.00164	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—bone cancer	6.88e-05	0.00164	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.81e-05	0.00162	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP3A4—bone cancer	6.76e-05	0.00161	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	6.67e-05	0.00159	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6.51e-05	0.00155	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	6.49e-05	0.00155	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MMP9—bone cancer	6.28e-05	0.0015	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—bone cancer	6.18e-05	0.00147	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	6.1e-05	0.00145	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	6.1e-05	0.00145	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NT5C3A—bone cancer	5.93e-05	0.00141	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GSTP1—bone cancer	5.78e-05	0.00138	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	5.7e-05	0.00136	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	5.6e-05	0.00134	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.58e-05	0.00133	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—bone cancer	5.54e-05	0.00132	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—bone cancer	5.19e-05	0.00124	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CDK4—bone cancer	5.15e-05	0.00123	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MET—bone cancer	5.15e-05	0.00123	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NDUFA12—bone cancer	5.08e-05	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—bone cancer	5.07e-05	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.05e-05	0.0012	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.83e-05	0.00115	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.68e-05	0.00112	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.46e-05	0.00106	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.4e-05	0.00105	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.39e-05	0.00105	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP2—bone cancer	4.29e-05	0.00102	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—bone cancer	4.26e-05	0.00102	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NT5C3A—bone cancer	4.21e-05	0.001	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NDUFA12—bone cancer	4.05e-05	0.000966	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.58e-05	0.000853	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.45e-05	0.000822	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	3.45e-05	0.000822	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NT5C3A—bone cancer	3.36e-05	0.0008	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—bone cancer	3.23e-05	0.000769	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NDUFA12—bone cancer	3.13e-05	0.000745	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.11e-05	0.000742	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ENO2—bone cancer	3.1e-05	0.00074	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.9e-05	0.000691	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—DHFR—bone cancer	2.88e-05	0.000686	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—bone cancer	2.61e-05	0.000622	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ENO2—bone cancer	2.6e-05	0.00062	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NT5C3A—bone cancer	2.59e-05	0.000618	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.45e-05	0.000583	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—DHFR—bone cancer	2.41e-05	0.000575	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GNA11—bone cancer	2.25e-05	0.000537	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFBR2—bone cancer	2.09e-05	0.000497	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.05e-05	0.00049	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP3A4—bone cancer	2.04e-05	0.000487	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ENO2—bone cancer	1.84e-05	0.000439	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTP1—bone cancer	1.75e-05	0.000416	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—DHFR—bone cancer	1.71e-05	0.000407	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GNA11—bone cancer	1.6e-05	0.000381	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ENO2—bone cancer	1.47e-05	0.000351	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP3A4—bone cancer	1.45e-05	0.000345	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KIT—bone cancer	1.42e-05	0.000339	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—DHFR—bone cancer	1.36e-05	0.000325	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BRAF—bone cancer	1.34e-05	0.000319	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GNA11—bone cancer	1.28e-05	0.000304	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTP1—bone cancer	1.24e-05	0.000295	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP3A4—bone cancer	1.16e-05	0.000276	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.15e-05	0.000274	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ENO2—bone cancer	1.13e-05	0.000271	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MDM2—bone cancer	1.12e-05	0.000267	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—DHFR—bone cancer	1.05e-05	0.000251	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTP1—bone cancer	9.89e-06	0.000236	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GNA11—bone cancer	9.84e-06	0.000235	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—bone cancer	7.66e-06	0.000183	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTP1—bone cancer	7.63e-06	0.000182	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—bone cancer	6.42e-06	0.000153	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—bone cancer	5.12e-06	0.000122	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—bone cancer	3.95e-06	9.42e-05	CbGpPWpGaD
